Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo

Urovant Sciences' interim results from a Phase 2a trial of URO-902 gene therapy were presented at the annual meeting of the American Urological Association (AUA2022).
Urovant is a wholly-owned subsidiary of Sumitovant Biopharma Ltd.
Sumitovant, the Sumitomo Pharma subsidiary, is also the majority shareholder of Myovant Sciences Ltd MYOV.
The interim results support that in women with overactive bladder (OAB), not well managed by oral therapies, a single dose of URO-902 was safe and well-tolerated.
Of the 80 female patients who were randomized, 68 completed week 12 of the study, and 74 were included in the intent-to-treat population.
At week 12, both URO-902 24 mg and 48 mg were associated with a clinically relevant improvement compared with placebo in mean daily micturition (urination), urgency episodes, UUI episodes, OAB bother score, and proportion of patient global impression of change responders.
Treatment-emergent adverse events occurred in 45.5% of patients receiving URO-902 24 mg, 46.2% receiving 48 mg, and 50.0% receiving placebo. The most commonly occurring adverse event was urinary tract infection.
Price Action: MYOV shares are up 5.05% at $9.05 during the market session on the last check Friday.